Absci Corp 8-K

What Happened
On June 24, 2026, Absci Corporation (ABSI) filed a Current Report on Form 8‑K (Item 8.01) to announce interim Phase 1 data from the HEADLINE™ clinical trial of its investigational therapy ABS‑201. The company issued a press release dated June 24, 2026 reporting the update; that press release is attached to the 8‑K as Exhibit 99.1.

Key Details

• Filing date: June 24, 2026 (Form 8‑K, Item 8.01 – Other Events).
• Press release announcing the interim Phase 1 data is included as Exhibit 99.1 to the 8‑K.
• Investigational product: ABS‑201; clinical program referenced: HEADLINE™ trial.
• Report signed on behalf of the company by Shelby Walker, Chief Legal Officer.

Why It Matters
Clinical data updates are material for biotech investors because they can affect development timelines, regulatory strategy, partnership interest and market expectations. This 8‑K formally notifies investors that Absci is sharing interim Phase 1 results; investors should read the attached press release (Exhibit 99.1) for the specific safety, efficacy, enrollment and next‑step details and monitor the company for follow‑up disclosures and regulatory/clinical milestones.